Information Provided By:
Fly News Breaks for March 21, 2018
INSM
Mar 21, 2018 | 08:13 EDT
Morgan Stanley analyst Matthew Harrison started Insmed with an Overweight rating and $39 price target, as he believes data from its treatment of nontuberculous mycobacteria is strong enough that he estimates $400M-500M of peak U.S. sales. However, while Harrison thinks the market sees the value in the refractory population, it appears to be missing the key upside drivers of expansion into maintenance therapy, geographic expansion to Japan and potentially even frontline treatment, he tells investors.
News For INSM From the Last 2 Days
INSM
INSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.